Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Technology Stocks News 10

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session and the average volume of the stock remained 2.24million shares. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider ownership is 5.70%.

Omeros Corporation (NASDAQ:OMER) Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764.Omeros Corporation (NASDAQ:OMER) rose 8.92 percent to $17.47 Wednesday on volume of 1.15million shares. The intra-day range of the stock was $16.20 to $17.72. Omeros Corporation (NASDAQ:OMER) has a market capitalization of $592.45million.

Insys Therapeutics Inc (NASDAQ:INSY) Director John N. Kapoor bought 5,000 shares of the company’s stock on the open market in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $25.44 per share, for a total transaction of $127,200.00. Following the transaction, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $406,811. Insys Therapeutics Inc (NASDAQ:INSY)’s stock on June 25, 2014 reported a increase of 6.51% to the closing price of $30.90. Its fifty two weeks range is $7.78 -$57.91. The total market capitalization recorded $1.06billion. The overall volume in the last trading session was 805,607.00million shares. In its share capital, INSY has 34.23million outstanding shares.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Director John Maraganore bought $101,154 worth of company, buying 2,300 shares at a cost of $43.98 each. Before this latest buy, Maraganore bought AGIO at 2 other times during the past twelve months, for a total cost of $248,994 at an average of $23.53 per share. On Wednesday, shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) dropped -0.09% to close the day at $43.84. Company return on investment (ROI) is -30.00% and its monthly performance is recorded as 21.31%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly revenue growth is 20.97%.

BioTime Inc (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average cost of $2.50 per share, with a total value of $2,500,000.00. BioTime, Inc. (NYSEMKT:BTX) stock performance was 3.57% in last session and finished the day at $3.19. Traded volume was 204,151.00million shares in the last session and the average volume of the stock remained 264.96K shares. The beta of the stock remained 1.30. BioTime, Inc. (NYSEMKT:BTX) insider ownership is 9.40%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone